Trial · NCT07897825
FINtick - a Prospective Multicenter Study on Tick-borne Infections in Finland
NCT07897825, Recruiting, Turku University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FINtick - a Prospective Multicenter Study on Tick-borne Infections in Finland. Trials, record NCT07897825. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897825
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FINtick - a Prospective Multicenter Study on Tick-borne Infections in Finland
- NCT number
- NCT07897825
- Status
- Recruiting
- Enrollment
- 850 participants, estimated
- Lead sponsor
- Turku University Hospital
- Conditions
- Tick Borne Encephalitis (TBE), Lyme Borreliosis, Neoehrlichiosis, Tick-Borne Diseases, Anaplasmosis, Babesiosis, Human, Rickettsia Infections, Borrelia Miyamotoi -Infection
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The number of diagnosed neoehrlichiosis cases | From enrollment to the end of the follow-up at 6 months. | The number of patients in whose plasma (EDTA blood sample) Neoehrlichia mikurensis nucleic acid can be detected by a nucleic acid amplification test (NAAT). |
| Primary | The number of diagnosed cases with Borrelia miyamotoi -infection | From enrollment to the end of follow-up at 6 months | The number of patients in whose blood or cerebrospinal fluid sample Borrelia miyamotoi nucleic acid can be detected by a nucleic acid amplification test (NAAT). |
| Primary | The number of diagnosed babesiosis cases | From enrollment to the end of follow-up at 6 months | The number of patients with laboratory evidence of Babesia infection in a blood sample, detected by blood smear microscopy or nucleic acid amplification test. |
| Primary | The number of diagnosed anaplasmosis cases | From enrollment to the end of follow-up at 6 months | The number of patients with laboratory-confirmed Anaplasma phagocytophilum infection, demonstrated either by seroconversion in paired serum samples together with symptoms or by detection of nucleic acid in a blood sample using a nucleic acid amplification test (NAAT). |
| Primary | The number of diagnosed rickettsiosis cases | From enrollment to the end of follow-up at 6 months | The number of patients with laboratory-confirmed Rickettsia spp. infection, demonstrated either by seroconversion in paired serum samples together with symptoms or by detection of nucleic acid in a blood sample using a nucleic acid amplification test (NAAT). |
| Primary | The number of diagnosed Lyme borreliosis cases | From enrollment to the end of follow-up at 6 months | The number of patients diagnosed with Lyme borreliosis according to the European clinical case definitions (Stanek G, Fingerle V, Hunfeld K-P, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011;17(1):69-79). |
| Primary | The number of diagnosed tick-borne encephalitis cases | From enrollment to the end of follow-up at 6 months | The number of patients diagnosed with tick-borne encephalitis (TBE), confirmed either by serology or by a nucleic acid amplification test (NAAT). |
| Secondary | EuroQoL-5 Dimension Questionnaire (EQ-5D) | 6 months | Difference in EQ-5D Health index between study inclusion and at the 6 month-follow-up |
| Secondary | Visual Analogue Scale for Health (VAS) from 0 to 100 (100 best) | 6 months | Difference between the VAS units at study inclusion and at 6 month-follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897825
GET https://conductscience.org/api/trials/v1/NCT07897825/registered